Researchers say the approach could offer a new direction for tackling drug-resistant bacterial infections, although further research is needed before it can be tested in people. In recent years, health experts have reported increased antimicrobial resistance in gonorrhoea, reducing the number of effective treatment options available. The antibody guides the treatment directly to N. gonorrhoeae, while the antimicrobial component remains inactive until it reaches the bacterium. In laboratory experiments, the targeted therapy killed a multidrug-resistant gonococcal strain that is resistant to current first-line antibiotics. The paper `An antibody–drug conjugate active against antibiotic-resistant Neisseria gonorrhoeae’ (doi/10.1073/pnas.2534217123) was published in PNAS.